Ana Clara Santos Costa

Ana Clara Santos Costa

Auto-generated profile, based on publicly available information

Ana Clara Santos Costa

Laboratory of Immunomodulation and New Therapeutic Approaches, Center for Research in Therapeutic Innovation – Suely Galdino (NUPIT‐SG), Center for Biosciences – CB Federal University of Pernambuco Recife Pernambuco Brazil

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Cytokine
Verified
Journal Article
Closed access
RBRodrigo José Videres Cordeiro de Brito
Rodrigo José Videres Cordeiro de Brito
RCRodrigo Carmo
Rodrigo Carmo
BSBruna Manuella Souza Silva
Bruna Manuella Souza Silva
ACAna Clara Santos Costa
Ana Clara Santos Costa
SRSura Wanessa Santos Rocha
Sura Wanessa Santos Rocha
Patricia MouraPatricia Moura
Patricia Moura

14 October 2025 in Journal of Medical Virology
Verified
Journal Article
Open access
ACAna Clara Santos Costa
Ana Clara Santos Costa
ASAnderson Felix dos Santos
Anderson Felix dos Santos
GAGabriela Cavalcanti Lima Albuquerque
Gabriela Cavalcanti Lima Albuquerque
MRMichelle Melgarejo da Rosa
Michelle Melgarejo da Rosa
JTJamile Taniele‐Silva
Jamile Taniele‐Silva
MRMoacyr Rêgo
Moacyr Rêgo
Chikungunya virus (CHIKV) infection can trigger a sustained inflammatory response, often leading to chronic musculoskeletal pain. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) may contribute to the persistence of arthralgia through their involvement in joint tissue remodeling and degradation. This study aimed to evaluate the potential of MMPs and TIMPs as plasma biomarkers of persistent arthralgia in individuals diagnosed with Chikungunya Fever (CHIKF). A prospective cohort study was conducted using plasma samples from 133 CHIKF‐positive individuals recruited during the acute or post‐acute phases. Sociodemographic and clinical data were collected at outpatient visits. At 90 days post‐symptom onset, participants were assessed for persistent arthralgia using a self‐reported Visual Analog Scale (VAS) for joint pain and categorized into two groups: Recovered (VAS 0–3, n = 71) or Persistent Arthralgia (VAS 4–10, n = 62). Plasma levels of MMP‐2, MMP‐9, and TIMP‐2 were quantified using multiplex bead‐based ELISA (LegendPlex), while MMP‐1, MMP‐3, MMP‐14/MT1‐MMP, and TIMP‐1 were measured via sandwich ELISA. Plasma samples from 51 CHIKV‐negative individuals were used as controls. Statistical analyzes were performed using GraphPad Prism v9.0, IBM SPSS Statistics and Stata. Among post‐acute participants, lower MMP‐2 levels were significantly associated with recovery compared to those with persistent arthralgia and to controls. TIMP‐2 levels varied significantly across clinical outcomes, supporting its involvement in CHIKV‐induced pathology. Multivariate analysis identified swollen joints, skin rash, and elevated TIMP‐2 levels during the post‐acute phase as independent predictors of persistent arthralgia in the chronic phase. No significant differences were observed for MMP‐1, MMP‐3, MMP‐9, MMP‐14, or TIMP‐1. These findings suggest a potential role for TIMP‐2 and musculoskeletal manifestations as early indicators of chronic joint symptoms following CHIKV infection. Further studies are needed to validate these biomarkers and better understand the mechanisms underlying chronic Chikungunya‐related arthralgia across diverse populations.

1 January 2000 in Journal of Hepatology
Verified
Journal Article
Closed access
PDF file
FSF. Serejo
F. Serejo
ACA. Costa
A. Costa
FRF. Ramalho
F. Ramalho
ABA. Batista
A. Batista
MMM.C. Moura
M.C. Moura

10 December 2020 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
LCLetícia Nunes Campos
Letícia Nunes Campos
ACAna Clara Santos Costa
Ana Clara Santos Costa
DCDébora Cerqueira
Débora Cerqueira
GRGabriele Rodrigues Rangel
Gabriele Rodrigues Rangel
IAIsabela Cristina de Farias Andrade
Isabela Cristina de Farias Andrade
SRSura Wanessa Santos Rocha
Sura Wanessa Santos Rocha
Coronaviruses are a large viral family, whose infections are recognized since 1960, varying from the common cold to more critical respiratory conditions. Regarding coronavirus 2019 (COVID-19), a wide spectrum of neurological manifestations among infected patients were reported, raising concerns whether Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) had tropism for the central nervous system. To clarify these questions, this bibliographic review was carried out by searching for articles based on national and international data during the period from December 2019 to June 2020. Thus, this review summarizes the current evidence on the transmission routes, focusing on the olfactory bulb and the hematogenic pathways, as well as the direct and indirect pathological mechanisms through which SARS-CoV-2 causes neurological damage. Moreover, clinical, laboratorial, and therapeutic aspects to manage patients with COVID-19 related neurological symptoms are outlined. Finally, development of treatments tackling specific structures and pathways related to viral entry and cardiovascular regulation on the brain are expected, in addition to monitoring of patients affected by the COVID-19 to assess long-term consequences on the nervous system.